Clinical Trial

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-10-01; most recent amendment 2026-07-15.
Trial Details
NCT Number NCT07209449
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Endometrial Cancer
Enrollment 75 participants
Start Date 2025-10-01
Primary Completion 2028-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-16